Compare LITB & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LITB | EVAX |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | Singapore | Denmark |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.7M | 31.9M |
| IPO Year | 2013 | 2020 |
| Metric | LITB | EVAX |
|---|---|---|
| Price | $2.06 | $4.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 9.3K | ★ 31.2K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.50 | N/A |
| Revenue Next Year | $11.59 | $328.20 |
| P/E Ratio | $10.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $1.42 |
| 52 Week High | $4.17 | $12.15 |
| Indicator | LITB | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 47.70 | 62.84 |
| Support Level | $1.88 | $2.64 |
| Resistance Level | $2.25 | $4.62 |
| Average True Range (ATR) | 0.13 | 0.33 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 36.36 | 70.00 |
LightInTheBox Holding Co Ltd is a e-commerce company, providing a diverse range of affordable lifestyle products directly to consumers. Its brands include Ador, a women's fashion brand targeting women aged 35-55; the second is a golf apparel brand focusing on female golfers aged 35 and above; the third is a women's light party dress brand for the age group of 30 and above. It offers customers products through websites and mobile applications. The company operates and reviews its performance in two segments: Product sales which consisted of online retailing of consumer products and sales to third-party sellers, and Services which consisted of the provision of logistic services to companies and individual customers.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.